Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04 2023 - 07:00AM
GlobeNewswire Inc.
Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology
company developing induced pluripotent stem cell (iPSC)-derived
cell therapies in immuno-oncology, today announced that Lalo
Flores, Ph.D., Chief Executive Officer, will present at the 41st
Annual J.P. Morgan Healthcare Conference on Wednesday, January 11,
2023 at 9:45 AM PT.
A live webcast of the event will be available on
the Events & Presentations page of Century’s website. A replay
of the webcast will be archived on the Company's website for a
limited time.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is harnessing
the power of adult stem cells to develop curative cell therapy
products for cancer that we believe will allow us to overcome the
limitations of first-generation cell therapies. Our genetically
engineered, iPSC-derived iNK and iT cell product candidates are
designed to specifically target hematologic and solid tumor
cancers. We are leveraging our expertise in cellular reprogramming,
genetic engineering, and manufacturing to develop therapies with
the potential to overcome many of the challenges inherent to cell
therapy and provide a significant advantage over existing cell
therapy technologies. We believe our commitment to developing
off-the-shelf cell therapies will expand patient access and provide
an unparalleled opportunity to advance the course of cancer care.
For more information on Century Therapeutics please
visit www.centurytx.com.
Century Therapeutics Forward-Looking
Statement
This press release contains forward-looking
statements within the meaning of, and made pursuant to the safe
harbor provisions of, The Private Securities Litigation Reform Act
of 1995. In some cases, you can identify forward-looking statements
by terms such as “may,” “might,” “will,” “should,” “expect,”
“plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplate,” “believe,” “estimate,” “predict,”
“forecast,” “potential” or “continue” or the negative of these
terms or other similar expressions. These statements are not
guarantees of future performance These risks and uncertainties are
described more fully in the “Risk Factors” section of our most
recent filings with the Securities and Exchange Commission and
available at www.sec.gov. You should not rely on these
forward-looking statements as predictions of future events. The
events and circumstances reflected in our forward-looking
statements may not be achieved or occur, and actual results could
differ materially from those projected in the forward-looking
statements. Except as required by applicable law, we do not plan to
publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events,
changed circumstances or otherwise.
For More Information: Company:
Elizabeth Krutoholow – investor.relations@centurytx.comInvestors:
Melissa Forst/Maghan Meyers – century@argotpartners.comMedia:
Joshua R. Mansbach – century@argotpartners.com
Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart
From Feb 2023 to Mar 2023
Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart
From Mar 2022 to Mar 2023